AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10368942 — intervention group
Group type: EXPERIMENTAL
Intervention: Different variable-interval schedule
Number of subjects: 15
Study 10368942 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction condition
Number of subjects: 15
Study 10368942 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition (same schedule of reinforcement)
Number of subjects: 15
Study 8874257 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. dobutamine (n = 13)
Number of subjects: 29
Study 8874257 — intervention group
Group type: EXPERIMENTAL
Intervention: milrinone (n = 10)
Number of subjects: 29
Study 8874257 — intervention group
Group type: EXPERIMENTAL
Intervention: diuretic responsive (group A; n = 6)
Number of subjects: 29
Study 8874257 — intervention group
Group type: EXPERIMENTAL
Intervention: diuretic resistant (group B; n = 23)
Number of subjects: 29
Study 8874257 — intervention group
Group type: COMPARATOR
Intervention: healthy control subjects (n = 25)
Number of subjects: 29
Study 8874257 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week after hospital discharge (group A)
Number of subjects: 29
Study 8874257 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week after hospital discharge (group B)
Number of subjects: 29
Study 1517949 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio 60/40
Number of subjects: 0
Study 1517949 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio 50/50
Number of subjects: 0
Study 1517949 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio 35/65
Number of subjects: 0
Study 1517949 — intervention group
Group type: COMPARATOR
Intervention: Human milk protein (HMP)‐fortified human milk
Number of subjects: 0
Study 6385261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-mitoxantrone-5-fluorouracil
Number of subjects: 44
Study 6385261 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide-doxorubicin-5-fluorouracil
Number of subjects: 44
Study 31882015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative VR immersion
Number of subjects: 40
Study 31882015 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 40
Study 29857856 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging training for investigators
Number of subjects: 1069
Study 29857856 — intervention group
Group type: EXPERIMENTAL
Intervention: Local investigators' assessment of imaging criteria
Number of subjects: 1069
Study 29857856 — intervention group
Group type: EXPERIMENTAL
Intervention: Local investigators' assessment of DWI-FLAIR mismatch
Number of subjects: 1069
Study 27507131 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic load diet
Number of subjects: 82
Study 24169211 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 positive men (PCA3 ≥ 35) underwent initial biopsy (IBx) - 12 cores.
Number of subjects: 2366
Study 24169211 — intervention group
Group type: COMPARATOR
Intervention: Men randomized to observation (PCA3 < 35)
Number of subjects: 2366
Study 24169211 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 positive group
Number of subjects: 2366
Study 24169211 — intervention group
Group type: COMPARATOR
Intervention: PCA3 negative group
Number of subjects: 2366
Study 24169211 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 as a second line biomarker
Number of subjects: 2366
Study 22376194 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week (5×/week) aerobic cycling training with lower limb weights
Number of subjects: 133
Study 22376194 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity overground walking
Number of subjects: 133
Study 19530976 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin PDT
Number of subjects: 364
Study 19530976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 17977860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (warning of a 'sting')
Number of subjects: 101
Study 17977860 — intervention group
Group type: COMPARATOR
Intervention: Group NS (no warning of a 'sting')
Number of subjects: 101
Study 15310639 — intervention group
Group type: COMPARATOR
Intervention: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1)
Number of subjects: 80
Study 15310639 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 2 microg.kg(‐1)
Number of subjects: 80
Study 15310639 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 3 microg.kg(‐1)
Number of subjects: 80
Study 15310639 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal 0.25% plain bupivacaine 0.5 mL.kg(‐1) with neostigmine 4 microg.kg(‐1)
Number of subjects: 80
Study 11781224 — intervention group
Group type: EXPERIMENTAL
Intervention: High-purity factor VIII/von Willebrand factor concentrate
Number of subjects: 81
Study 9846530 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and prednisone (double-drug therapy)
Number of subjects: 200
Study 9846530 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus, prednisone, and mycophenolate mofetil (triple-drug therapy)
Number of subjects: 200
Study 7747094 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 150
Study 7747094 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin 150 mg bid for 10 days
Number of subjects: 150
Study 2687356 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg haloperidol i.v.
Number of subjects: 6
Study 2687356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1098396 — intervention group
Group type: EXPERIMENTAL
Intervention: methyldopa, 750 mg/day
Number of subjects: 28
Study 1098396 — intervention group
Group type: EXPERIMENTAL
Intervention: spironolactone, 200 mg/day
Number of subjects: 28
Study 1098396 — intervention group
Group type: EXPERIMENTAL
Intervention: combined treatment with spironolactone and methyldopa
Number of subjects: 28
Study 1098396 — intervention group
Group type: EXPERIMENTAL
Intervention: spironolactone, 100 mg/day
Number of subjects: 28
Study 1098396 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 31969343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Phone Counseling
Number of subjects: 1196
Study 31969343 — intervention group
Group type: COMPARATOR
Intervention: Tailored Web intervention
Number of subjects: 1196
Study 31969343 — intervention group
Group type: COMPARATOR
Intervention: Tailored Web + Phone intervention
Number of subjects: 1196
Study 31969343 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1196
Study 30717797 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks (1 L‐mn subgroup)
Number of subjects: 150
Study 30717797 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks (2 L subgroup)
Number of subjects: 150
Study 28911141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular glucagon administration
Number of subjects: 37
Study 28911141 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro glucagon treatment
Number of subjects: 37
Study 26285330 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneo- and peloid therapy using sulfide-containing siltypeloids
Number of subjects: 186
Study 23638898 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosage-continued group (n=14)
Number of subjects: 54
Study 23638898 — intervention group
Group type: COMPARATOR
Intervention: Step-down group (n=15)
Number of subjects: 54
Study 21195942 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management
Number of subjects: 902
Study 21195942 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 902
Study 20205017 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (affirming a personally important value)
Number of subjects: 84
Study 20205017 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (affirming a personally unimportant value)
Number of subjects: 84
Study 17999271 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behaviour therapy (ICBT)
Number of subjects: 29
Study 17999271 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive-behaviour therapy (GCBT)
Number of subjects: 29
Study 17999271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICBT and GCBT
Number of subjects: 29
Study 15467325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training (TG; n=13; 6 men) - 24 exercise sessions, intensity at 80% of maximal HR, load increase based on dyspnea scores
Number of subjects: 25
Study 15467325 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n=12; 6 men) - no intervention
Number of subjects: 25
Study 11245506 — intervention group
Group type: EXPERIMENTAL
Intervention: Air enriched with 3% CO2 during and for 10 minutes after exercise
Number of subjects: 10
Study 11245506 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 10
Study 9926053 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based services (intensive care)
Number of subjects: 286
Study 9926053 — intervention group
Group type: COMPARATOR
Intervention: Community-based services (standard care)
Number of subjects: 286
Study 9926053 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based services (both intensive and standard care)
Number of subjects: 286
Study 9926053 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based services (general)
Number of subjects: 286
Study 7531432 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 497
Study 7531432 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 497
Study 2923963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.0 g daily)
Number of subjects: 8
Study 2923963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (1.2 g daily)
Number of subjects: 8
Study 2923963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2923963 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 133238 — intervention group
Group type: COMPARATOR
Intervention: Constant torque load offered by an electric motor with perturbations introduced at random during flexion movements.
Number of subjects: 8
Study 133238 — intervention group
Group type: COMPARATOR
Intervention: Increased initial load by a factor of 10.
Number of subjects: 8
Study 133238 — intervention group
Group type: COMPARATOR
Intervention: Relaxed muscle stretching.
Number of subjects: 8
Study 133238 — intervention group
Group type: COMPARATOR
Intervention: Fatigued muscle activation.
Number of subjects: 8
Study 30921578 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Dynamic Tape
Number of subjects: 50
Study 30921578 — intervention group
Group type: COMPARATOR
Intervention: Sham Dynamic Tape
Number of subjects: 50
Study 30530462 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention (LowSalt4Life) for 8 weeks
Number of subjects: 50
Study 30530462 — intervention group
Group type: COMPARATOR
Intervention: Usual care (dietary advice) for 8 weeks
Number of subjects: 50
Study 27075417 — intervention group
Group type: EXPERIMENTAL
Intervention: ENRICH six session face-to-face healthy lifestyle program
Number of subjects: 174
Study 27075417 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 174
Study 25230216 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 25
Study 22781020 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐WWB (white wheat bread enriched with guar gum)
Number of subjects: 40
Study 22781020 — intervention group
Group type: COMPARATOR
Intervention: WWB (high glycaemic index white wheat bread)
Number of subjects: 40
Study 20656965 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training (15 hours)
Number of subjects: 83
Study 20656965 — intervention group
Group type: COMPARATOR
Intervention: Cognitive rehabilitation therapy
Number of subjects: 83
Study 20656965 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 83
Study 20656965 — intervention group
Group type: EXPERIMENTAL
Intervention: Current drivers
Number of subjects: 83
Study 17336254 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression with antithymocyte globulin
Number of subjects: 0
Study 17336254 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 17336254 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine and decitabine
Number of subjects: 0
Study 17336254 — intervention group
Group type: COMPARATOR
Intervention: General therapies for MDS
Number of subjects: 0
Study 16249542 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time graphical phone-based feedback for the previous 2 weeks with nurse-initiated support using a web-based graphical analysis of glucose self-monitoring results.
Number of subjects: 93
Study 16249542 — intervention group
Group type: COMPARATOR
Intervention: Glucose self-monitoring real-time result transmission and feedback of results for the previous 24 hours.
Number of subjects: 93
Study 11877349 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe CHF patients
Number of subjects: 16
Study 11877349 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 16
Study 11877349 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF patients
Number of subjects: 16
Study 10334256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17 beta-oestradiol (S21400) 100 microg, 200 microg, 300 microg, or 400 microg
Number of subjects: 420
Study 10334256 — intervention group
Group type: COMPARATOR
Intervention: Oral oestradiol valerate 1 mg or 2 mg
Number of subjects: 420
Study 10334256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17 beta-oestradiol (S21400)
Number of subjects: 420
Study 8726096 — intervention group
Group type: EXPERIMENTAL
Intervention: Large meals
Number of subjects: 7
Study 8726096 — intervention group
Group type: COMPARATOR
Intervention: Small meals
Number of subjects: 7
Study 2249117 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavoxate
Number of subjects: 0
Study 2249117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6795915 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 10
Study 6795915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 10
Study 6795915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 10
Study 31328306 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute apple cider vinegar (0.5% acetic acid)
Number of subjects: 22
Study 31328306 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 22
Study 28045958 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEGF (50 microg/mL)
Number of subjects: 138
Study 28045958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 26031745 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior dynamic stabilization (PDS)
Number of subjects: 176
Study 26031745 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 176
Study 26031745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PDS and PLIF
Number of subjects: 176
Study 25189743 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying water
Number of subjects: 16
Study 25189743 — intervention group
Group type: COMPARATOR
Intervention: Carrying iron
Number of subjects: 16
Study 25189743 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying weight (4.4, 8.9, 13.3, 17.8 kg)
Number of subjects: 16
Study 25189743 — intervention group
Group type: EXPERIMENTAL
Intervention: Base area of container (24 × 24 cm, 35 × 24 cm)
Number of subjects: 16
Study 25189743 — intervention group
Group type: EXPERIMENTAL
Intervention: Water occupying 60%-80% of full volume of the container
Number of subjects: 16
Study 22892731 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoVac irrigation (n = 25)
Number of subjects: 48
Study 22892731 — intervention group
Group type: COMPARATOR
Intervention: Standard needle irrigation (control group, n = 23)
Number of subjects: 48
Study 20868384 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic fibroblast growth factor (bFGF) spray daily
Number of subjects: 40
Study 20868384 — intervention group
Group type: COMPARATOR
Intervention: Control group (only skin grafting)
Number of subjects: 40
Study 17358099 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1.5 mg/kg
Number of subjects: 120
Study 17358099 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 1 microg/kg
Number of subjects: 120
Study 17358099 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine 1.5 mg/kg
Number of subjects: 120
Study 17358099 — intervention group
Group type: COMPARATOR
Intervention: dextrose 5% 5 mL (control)
Number of subjects: 120
Study 15848532 — intervention group
Group type: COMPARATOR
Intervention: Group A (stopped steroids)
Number of subjects: 113
Study 15848532 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (continued steroids)
Number of subjects: 113
Study 15848532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 11981384 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment (60 mW, transmeatal, once a week for 6 minutes, 4 times over 4 weeks)
Number of subjects: 45
Study 11981384 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment (transmeatal, once a week for 6 minutes, 4 times over 4 weeks)
Number of subjects: 45
Study 9809620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis lung transplant recipients
Number of subjects: 38
Study 7696766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic technique A
Number of subjects: 0
Study 7696766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic technique B
Number of subjects: 0
Study 2636655 — intervention group
Group type: COMPARATOR
Intervention: Mildly protein-restricted control diet
Number of subjects: 95
Study 2636655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein, low phosphorus diets (three types)
Number of subjects: 95
Study 7446572 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt rehearsal
Number of subjects: 300
Study 7446572 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert rehearsal
Number of subjects: 300
Study 7446572 — intervention group
Group type: COMPARATOR
Intervention: Immediate recall
Number of subjects: 300
Study 7446572 — intervention group
Group type: COMPARATOR
Intervention: 20-second unfilled interval
Number of subjects: 300
Study 7446572 — intervention group
Group type: COMPARATOR
Intervention: 20-second interval filled with interpolated mental activity
Number of subjects: 300
Study 7446572 — intervention group
Group type: COMPARATOR
Intervention: 20-second interval of overt rehearsal
Number of subjects: 300
Study 7446572 — intervention group
Group type: COMPARATOR
Intervention: 20-second interval filled with simultaneous overt rehearsal and interpolated mental activity
Number of subjects: 300
Study 30003519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit Down and Play (SDP)
Number of subjects: 40
Study 30003519 — intervention group
Group type: COMPARATOR
Intervention: Control group (handouts regarding developmental milestones)
Number of subjects: 40
Study 27466719 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone elastomer (SE) contact lenses
Number of subjects: 57
Study 27466719 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (GP) contact lenses
Number of subjects: 57
Study 27466719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lens types
Number of subjects: 57
Study 27466719 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratometric power
Number of subjects: 57
Study 27466719 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratometric astigmatism
Number of subjects: 57
Study 27466719 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens-related adverse events
Number of subjects: 57
Study 25219358 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CTC telomerase activity (TA) in patients with baseline CTC count ≥5
Number of subjects: 263
Study 25219358 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CTC TA
Number of subjects: 263
Study 25219358 — intervention group
Group type: EXPERIMENTAL
Intervention: High CTC TA
Number of subjects: 263
Study 23246896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet-C (UVC) irradiation
Number of subjects: 43
Study 23246896 — intervention group
Group type: COMPARATOR
Intervention: Placebo-UVC
Number of subjects: 43
Study 20561878 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (88.2%‐85.7%)
Number of subjects: 232
Study 20561878 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins or cholesterol‐lowering drugs (88.6%‐87%)
Number of subjects: 232
Study 20561878 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (68%‐55.6%)
Number of subjects: 232
Study 20561878 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmics
Number of subjects: 232
Study 20561878 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 232
Study 19694996 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT-treated PLT concentrates
Number of subjects: 66
Study 19694996 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated PLTs)
Number of subjects: 66
Study 19231245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg intravenously during anesthetic induction)
Number of subjects: 58
Study 19231245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 58
Study 19231245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 58
Study 19231245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15883757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg and 1 mg)
Number of subjects: 40
Study 15883757 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (70 mg and 70 mg)
Number of subjects: 40
Study 11755283 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (EF)
Number of subjects: 2948
Study 11755283 — intervention group
Group type: EXPERIMENTAL
Intervention: End-systolic volume index (ESVI)
Number of subjects: 2948
Study 11755283 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct size (IS)
Number of subjects: 2948